title: Breast Cancer: Blocking both driver and escape pathways improves outcomes.
authors.forename: Mothaffar F
authors.initials: MF
authors.lastname: Rimawi
authors.forename: C Kent
authors.initials: CK
authors.lastname: Osborne
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000187:drug effects; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors* / Q000187:drug effects; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016387:Women's Health
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068338:Everolimus; D007166:Immunosuppressive Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D020123:Sirolimus; C485206:pertuzumab